Back to mobile site
Get it on Google Play

Palisade Bio gets FDA clearance for Crohn's disease drug trial

September 22, 2026 8:35 AM EDT Send to a Friend
Palisade Bio, Inc. (Nasdaq: PALI) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login